Neuropacs Corp.'s MRI AI software earns FDA De Novo classification to assist in Parkinsonian syndrome diagnosis.
Key Details
- 1Neuropacs Corp. developed an AI-enabled MRI software targeting neurodegenerative disease evaluation.
- 2The tool differentiates between Parkinson’s disease, atypical parkinsonism, multiple system atrophy Parkinsonian variant, and progressive supranuclear palsy.
- 3FDA has granted the product De Novo classification, indicating novel technology.
- 4The software quantifies MRI data and aids in more accurate clinical decision-making.
Why It Matters
FDA De Novo clearance validates the clinical utility of this MRI-based AI tool, potentially supporting radiologists in systematizing diagnosis of challenging neurodegenerative syndromes. This may lead to more precise patient management and sets a precedent for AI-driven neuroimaging diagnostics.
Source
Radiology Business
Related News
•AuntMinnie
AI Advances in Breast Cancer Risk, CEUS Training Updates, and Imaging AI Variability
This week's top radiology news reviews AI advances in breast and lung cancer risk prediction, new CEUS training standards, and prostate screening updates with imaging modalities.
•AuntMinnie
Specialized AI Model Achieves 99% Accuracy in Cardiac MRI Interpretation
A cardiac MRI-specific AI algorithm, CMR-CLIP, demonstrated up to 99% accuracy for certain heart conditions, outperforming general AI models by up to 45.5%.
•Radiology Business
DeepHealth's Prostate AI Gains FDA Clearance for MRI Workflows
DeepHealth, a RadNet subsidiary, received FDA clearance for its AI solution to assist prostate cancer detection and MRI workflow.